MONMOUTH JUNCTION, N.J.,
Oct. 14, 2016 /PRNewswire/ --
CytoSorbents Corporation (NASDAQ: CTSO), a critical care
immunotherapy leader commercializing its flagship CytoSorb®
extracorporeal cytokine adsorber to treat deadly inflammation in
critically-ill and cardiac surgery patients around the world,
announced that CEO Dr. Phillip Chan,
MD, PhD, will present at the 2016 BIO Investor Forum taking place
October 18-19, 2016 in San Francisco. A live webcast of the
presentation will be available during and after the event.
Conference Presentation Details:
Where:
Westin St. Francis Hotel, 335 Powell St, San Francisco, CA 94102
When: Tuesday, October 18,
2016 at 4:30PM PDT
Room: Elizabethan A
Webcast:
https://www.veracast.com/webcasts/bio/investorforum2016/91130180661.cfm
Conference Website:
https://www.bio.org/events/bio-investor-forum
Currently, the company has limited availability to schedule
one-on-one meetings with institutional investors. To schedule a
meeting, please contact Lea Garcia
at lgarcia@cytosorbents.com.
About CytoSorbents Corporation (NASDAQ:
CTSO)
CytoSorbents Corporation is a leader in critical care
immunotherapy, specializing in blood purification. Its flagship
product, CytoSorb® is approved in the European Union with
distribution in 40 countries around the world, as a safe and
effective extracorporeal cytokine adsorber, designed to reduce the
"cytokine storm" or "cytokine release syndrome" that could
otherwise cause massive inflammation, organ failure and death in
common critical illnesses such as sepsis, burn injury, trauma, lung
injury and pancreatitis, as well as in cancer immunotherapy. These
are conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorb® is also being used during and
after cardiac surgery to remove inflammatory mediators, such as
cytokines and free hemoglobin, which can lead to post-operative
complications, including multiple organ failure. CytoSorbents has
completed its REFRESH (REduction in FREe Hemoglobin) 1 trial - a
multi-center, randomized controlled study that has demonstrated the
safety of intra-operative CytoSorb® use in a heart-lung machine
during complex cardiac surgery. In early 2017, the company plans to
initiate a pivotal REFRESH 2 trial intended to support U.S. FDA
approval. CytoSorb® has been used safely in more than 14,000 human
treatments to date.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant and contract funding in excess of $18
million from DARPA, the U.S. Army, the U.S. Air Force, the
U.S. Department of Health and Human Services, the National
Institutes of Health (NIH), National Heart, Lung, and Blood
Institute (NHLBI), U.S. Special Operations Command (SOCOM) and
others. The Company has numerous products under development based
upon this unique blood purification technology, protected by 32
issued U.S. patents and multiple applications pending, including
CytoSorb-XL, HemoDefend™, ContrastSorb, DrugSorb, and others. For
more information, please visit the Company's
websites: http://www.cytosorbents.com and http://www.cytosorb.com or
follow us on Facebook and Twitter.
About BIO and the BIO Investor Forum
BIO, the Biotechnology Innovation Organization, is the world's
largest trade association representing biotechnology companies,
academic institutions, state biotechnology centers and related
organizations across the United
States and in more than 30 other nations. BIO members are
involved in the research and development of innovative healthcare,
agricultural, industrial and environmental biotechnology products.
BIO also produces the BIO International Convention, the world's
largest gathering of the biotechnology industry, along with
industry-leading investor and partnering meetings held around the
world.
The BIO Investor Forum is an international biotechnology
investor conference focused on early and established private
companies as well as emerging public companies. The event features
plenary sessions, business roundtables and therapeutic workshops,
company presentations, and One-on-one Partnering™
meetings.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 9, 2016, as updated by the risks reported in
our Quarterly Reports on Form 10-Q, and in the press releases and
other communications to shareholders issued by us from time to time
which attempt to advise interested parties of the risks and factors
which may affect our business. We caution you not to place undue
reliance upon any such forward-looking statements. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, other than as required under the Federal securities
laws.
Please Click to Follow us on Facebook and Twitter
Cytosorbents
Contact: Amy Vogel
Investor
Relations
(732) 329-8885 ext.
*825
avogel@cytosorbents.com
|
Public Relations
Contact:
Amy
Phillips
Pascale Communications
412-327-9499
amy@pascalecommunications.com
|
Logo -
http://photos.prnewswire.com/prnh/20140408/MM00899LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cytosorbents-to-present-at-the-2016-bio-investor-forum-300344941.html
SOURCE CytoSorbents Corporation